
ProKidney (PROK) Stock Forecast & Price Target
ProKidney (PROK) Analyst Ratings
Bulls say
ProKidney is seeking approval for their autologous cell therapy, rilparencel, for the treatment of moderate to severe CKD and T2D, and the company's pipeline consists of the development program for severe diabetic kidney disease. With promising results from Phase 2 and agreement with the FDA to use eGFR slope as a surrogate endpoint for their BLA submission, ProKidney is well-positioned for upcoming milestones and potential market launch. While competition exists, ProKidney's therapy is currently the only one in Phase 3 trials and has the potential to delay the need for dialysis, making it a strong candidate in the market.
Bears say
ProKidney is a clinical-stage biotechnology company with a negative outlook due to the risks associated with their product, rilparencel. While the therapy has shown promise in trials, there is still uncertainty around its efficacy and regulatory approval. Additionally, the company's dependence on this one product and the limited market for this niche indication could pose challenges to its long-term success.
This aggregate rating is based on analysts' research of ProKidney and is not a guaranteed prediction by Public.com or investment advice.
ProKidney (PROK) Analyst Forecast & Price Prediction
Start investing in ProKidney (PROK)
Order type
Buy in
Order amount
Est. shares
0 shares